Franklyn Health’s decision to appoint Michael Branagan‑Harris as Senior Strategic Advisor marks a pivotal moment in our growth trajectory. It reflects not only our ambition, but our commitment to building a leadership team with the depth, credibility, and strategic insight required to support the most innovative medical technologies entering global markets.
Mike’s background is exceptional, even by MedTech standards. His career spans more than 35 years across clinical practice, commercial leadership, and high‑impact advisory work, giving him a rare, end‑to‑end understanding of how medical devices move from concept to widespread clinical adoption.
From RAF Paramedic to Global MedTech Leader
Scaling MedTech Success: Leveraging VNUS Expertise to achieve the Industry’s Best MedTech CRO Support at Franklyn Health
One of the most defining chapters of Mike’s career was his leadership of VNUS Medical Technologies UK, which he incorporated and grew into the company’s largest global subsidiary.
Under his direction:
- VNUS Closure®, a minimally invasive varicose vein treatment, achieved national recommendation from the NHS Innovation Centre, saving the NHS an estimated 50,000 bed days per year.
- The UK business became a multi‑million‑dollar operation, ultimately contributing to VNUS’s acquisition by Covidien in a $500M global transaction.
This track record demonstrates Mike’s ability to scale technologies, influence clinical adoption, and create substantial commercial value—skills that directly strengthen Franklyn Health’s strategic offering.
Scaling MedTech Success: How VNUS Experience Strengthens Franklyn Health’s CRO Capabilities
In 2010, Mike founded Device Access UK Ltd, a consultancy dedicated to helping medical device companies navigate the complex NHS reimbursement landscape. The company achieved extraordinary results:
- Supported 58+ successful NICE applications
- Delivered 1,000+ NHS “cases for change”
- Helped international MedTech companies secure UK market access through evidence‑driven strategies
This entrepreneurial success reinforces Mike’s deep expertise in health economics and market access; core pillars of Franklyn Health’s CRO services.
Why Michael Branagan‑Harris Strengthens Franklyn Health’s Position as the Top MedTech CRO
Franklyn Health is already recognised for its precision, agility, and specialist focus on MedTech clinical research. Mike’s appointment amplifies these strengths in several critical ways:
- A 360° Understanding of the MedTech Pathway
Few leaders understand the full lifecycle of a medical device from innovation to adoption as comprehensively as Mike. His experience spans:
- Clinical insight
- Regulatory and reimbursement strategy
- Commercial scaling
- Health economic modelling
- NHS engagement
This breadth allows Franklyn Health to support clients with not only rigorous clinical evidence, but the strategic foresight needed to ensure that evidence leads to real‑world adoption.
- Enhanced Credibility and Global Reach
Mike is widely recognised across the UK and international MedTech communities. His presence strengthens our visibility at:
- Global conferences
- Industry roundtables
- Regulatory and policy discussions
This elevates Franklyn Health’s profile and opens new opportunities for collaboration and growth.
- A More Integrated, End‑to‑End CRO Offering
Franklyn Health already excels in delivering high‑quality clinical research tailored to medical devices. With Mike’s advisory leadership, we now offer:
- Stronger early‑stage strategic planning
- More robust evidence‑to‑access pathways
- Greater alignment between clinical outcomes and commercial success
This combination is rare among CROs and increasingly essential in a competitive MedTech landscape.
Franklyn Health is creating the Stronger Future for MedTech Innovators
Ultimately, the greatest beneficiaries of this appointment are the innovators we serve. With Mike’s strategic insight and Franklyn Health’s operational excellence, clients gain a partner capable of navigating the complexities of development, evidence generation, and market access with confidence.
This milestone reflects Franklyn Health’s rapid growth.
